Adenocarcinoma of unknown primary site.
- Author:
Seo Young SONG
1
;
Won Seog KIM
;
Hye Ran LEE
;
Hyun Sik JEONG
;
Nam Su LEE
;
Sung Yong OH
;
Ji Hyang KIM
;
Kihyun KIM
;
Eun Mi NAM
;
Young Ryun OH
;
Chul Won JUNG
;
Sung Soo YOON
;
Young Hyuck IM
;
Hong Gui LEE
;
Won Ki KANG
;
Chan Hyung PARK
;
Keunchil PARK
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adenocarcinoma;
Unknown primary site
- MeSH:
Adenocarcinoma*;
Cisplatin;
Diaphragm;
Drug Therapy;
Humans;
Liver;
Lung;
Lymph Nodes;
Multivariate Analysis;
Neoplasm Metastasis;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Medicine
2001;61(3):234-239
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To study clinical characteristics and treatment outcomes of adenocarcinoma of unknown primary site (ACUPS). METHODS: A retrospective analysis of 81 patients who were diagnosed as ACUPS, seen at Samsung Medical Center from May, 1995 to July, 1999, was performed. RESULTS: The median age of the patients was 58 years. The common sites of metastases were the lymph node, liver, lung, bone. In 49 of 81 patients (60.5%), the dominant tumor location was below the diaphragm. The majority of patiens (76 of 81) were initially treated with systemic chemotherapy including cisplatin. Responses were evaluable in 70 of 76. Eighteen of 70 patients (25.7%) responded to chemotherapy and complete remission was observed in 6 patients. The overall median survival of 81 patients was 5.6 months. The median survival of the responding patients was 18.3 months but the median survial of the nonresponding patients was 4.6 months (p<0.01). In univariate and multivariate analysis, age, performance status and response to initial chemotherapy were significant prognostic factors for overall survial. CONCLUSION: Poor survival rate and treatment response were observed in ACUPS but complete response and long-term survival were observed in several patients.
